Multimodal Assesment of Alzheimer Patients

NCT06448403 · tracked via the Priya Life Science Norway tracker

Sponsor

Norwegian University of Science and Technology

Phase

Observational

Started

2024-07-01

Last updated

2026-08-13

Condition(s) studied

Mild Cognitive ImpairmentAlzheimer Disease, Late OnsetCognitive ImpairmentDementia

Investigational drug(s) / intervention(s)

MRI Scanning64-channel EEGPolysomnographyBlood samples →Fecal samplesCognitive tests

MRI Scanning: MRI scanning with volumetric, resting and activity-based sequences.

64-channel EEG: EEG to quantifiy electric activity.

Polysomnography: A randomized group will undergo polysomnography.

Blood samples: Analysis of specific blood biomarkers.

Fecal samples: Analysis of bacterial composition.

Cognitive tests: Interview-based cognitive tests for assesment of cognitive levels.

Study summary

The goal of this study is to learn more about the changes in the brains of patients with cognitive impairment (MCI) and Alzheimer's Disease (AD).

The main questions the study aims to answer are:

1. What findings can be used to earlier detect patients that will develop Alzheimers?
2. Which differences are seen between healthy and cognitively impaired patients?
3. Which differences are seen between patients with Alzheimers disease?

Participants will undergo:

* Cognitive tests
* Magnetic resonance imaging (MRI)
* Electroencephalography (EEG)
* Blood sample collection
* Fecal sample collection
* A randomized group will undergo polysomnography analysis.

Eligibility

Sex

ALL

Min age

65 Years

Max age

—

Healthy volunteers

Accepted

Inclusion Criteria: * MCI and AD according to relevant ICD-criterias. * Control cohort is age and gender matched with other cohorts. Exclusion Criteria: * Uneligibility for any of the planned neuroimagery devices (MRI, EEG) * AD diagnosis before the age of 65 (Early-onset AD). * Brain tumor * Traumtic head injury * Earlier neurosurgery * Other neyrodegenerative diseases (i.e Parkinson and ALS) * Diseases related to inflammation and auto-immunity (i.e MS)

Primary outcome measure(s)

MCI-AD converters — 5 years
Identify biomarker profiles unique for patients with MCI that develop AD for earlier prediction.
AD-subclassification — 5 years
Identify biomarker profiles that can assist in a more thorough AD-classification

Trial sites (1)

Facility	City	Region	Status
Norwegian University of Sciene and Technology / Norges teknisk-naturvitenskapelige universitet (NTNU)	Trondheim	Trønderlag	Recruiting

More Norwegian University of Science and Technology trials in Norway

MIDNOR-STROKE- a Long Term Follow-up Study of Patients With First Ever Ischemic Stroke in Central Norway Active, not recruiting

Goal Management Training for Adult Survivors of Childhood Leukemia and Non-Hodgkins Lymphoma With Neurocognitive Sequelae Active, not recruiting

Bariatric Surgery and Pharmacokinetics of Quetiapine Recruiting

Bariatric Surgery and Pharmacokinetics of Escitalopram Recruiting

Time-restricted Eating and High-intensity Interval Training After Gestational Diabetes Starting soon

Other trials for the same condition

Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen in Norway: A Prospective Cohort Study Active, not recruiting

REACT MCI - Repeated Advanced Cognitive Training in Mild Cognitive Impairment Active, not recruiting

Decoding Death and Dying in People With Dementia by Digital Thanotyping Recruiting

Dementia Choirs for Social and Psychological Wellbeing Active, not recruiting

Digital Intervention Targeting Cancer-related Cognitive Impairments Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06448403 on ClinicalTrials.gov ↗ ← All trials in Norway